Bioequivalence and Relative Bioavailability
Laboratorios Cinfa S.A. focuses on bioequivalence and relative bioavailability studies in healthy adult volunteers, comparing test and reference formulations under fed and fasting conditions.
- Comparative bioavailability assessments
- Test and reference product equivalence
- Healthy participant studies
These studies support the clinical evaluation of oral medicines intended for use in routine therapeutic settings.
Oral Solid Dosage Forms
The sponsor’s research includes film-coated tablets, modified-release tablets, prolonged-release tablets, and soft capsules, with attention to formulations designed for systemic delivery.
- Tablet and capsule formulations
- Modified-release and prolonged-release products
- Comparative formulation performance
Its portfolio reflects interest in dosage forms used across chronic and acute treatment areas.
Cardiometabolic and Metabolic Disorders
Clinical activity extends to medicines associated with type 2 diabetes, cardiometabolic disease, and related metabolic management, including combinations used to improve glycaemic control.
- Dapagliflozin
- Metformin hydrochloride
- Calcifediol
This area also includes therapies relevant to broader metabolic and endocrine care.
Neurology and Central Nervous System Therapies
The sponsor funds studies of medicines used in neurology and central nervous system care, with interest in agents for seizure control and mood-related disorders.
- Perampanel
- Vortioxetine
- Neurological and psychiatric treatment options
These trials reflect work across both neurological and neuropsychiatric therapeutic domains.
Urology and Anticoagulation
Research also covers therapies used in overactive bladder and thromboembolic risk reduction, including products with established roles in urology and anticoagulation.
- Mirabegron
- Apixaban
- Urological and cardiovascular medicine
These areas broaden the sponsor’s clinical interest across both chronic symptom management and vascular medicine.
